Biotech Values

[DewDiligence]

Dew was right. PSI-938 wasn't worth 3 out of the 11 billion GILD is paying for VRUS after-all.

You saved me the trouble of saying, “I told you so!” :- )

In all seriousness, I had no inkling that PSI-938 would run into trouble; rather, I simply didn’t think a drug so early in development could have been worth more than a few hundred million dollars in GILD’s valuation analysis.